Open Access Research
1College of Pharmacy, Al-Esraa University, Baghdad, Iraq
*Corresponding author: Marwan Mahtook, College of Pharmacy, Al-Esraa University, Baghdad, Iraq
Tel.: +964-(0) 7724449349
E-mail: marwan@esraa.edu.iq
Published: 5 May 2024; https://doi.org/10.61873/KMKM8961
Abstract
Musculoskeletal pain includes several types of discomfort associated with the skeletal system. Pharmaceutically, pridinol was developed in order to relax muscles. No empirical data exist to support the effectiveness of using meloxicam in combination therapy for the treatment of musculoskeletal pain. This study compared pridinol and meloxicam for musculoskeletal pain. The current observational study assessed a total of 82 patients. The study’s participants were divided into three groups: the “meloxicam” group, the “pridinol” group, and the “meloxicam + pridinol” group. Pain levels were measured before and four weeks after giving the drug, by using a visual analogue scale (VAS) and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). We employed a Kruskal-Wallis test in order to evaluate the variations in pain measurement among the groups. The three groups’ VAS and WOMAC scores did not differ before the drug administration. The “meloxicam + pridinol” treatment resulted in significant pain relief based on VAS and WOMAC scores at 1, 2, and 4 weeks (as compared to other groups; p<0.05). At 4 weeks, the VAS and WOMAC ratings exhibited no significant pain relief in the “meloxicam” group when compared to the “pridinol” group. The meloxicam-pridinol combination proved efficacious for musculoskeletal pain, and is recommended for its therapy.
Keywords: muscle cramps, spasm, meloxicam, pridinol, combination therapy
Please cite as:
Mahtook M., Saadi M., Alhameedawi S., Noor M. Obaid N.M., Alsaraf K. Real-world data on the effectiveness of the meloxicam and pridinol combination for musculoskeletal pain. Rev. Clin. Pharmacol. Pharmacokinet. Int. Ed. 38(Sup2): 141-144 (2024). https://doi.org/10.61873/KMKM8961